Semaglutide Dosage Guide

Titration schedules, clinical trial protocols, reconstitution, injection technique, side effect management, stacking considerations, and safety — for Ozempic, Wegovy, and compounded formulations.

Compiled by PeptideWiki Editorial Team·Last reviewed February 24, 2026

A leading innovator in research chemicals.

All products HPLC tested

|Exclusive Offer

Coupon

10%

Off

Use our affiliate link and code PEPTIDEWIKI at checkout to unlock your 10% discount, every time you use the code.

Shop Now

For research purposes only. PeptideWiki may earn a commission at no extra cost to you.

Research Peptides

Semaglutide

For research purposes only. PeptideWiki may earn a commission at no extra cost to you.

What Is Semaglutide?

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. It mimics the naturally occurring incretin hormone GLP-1, which is released from the gut after eating. By binding to GLP-1 receptors in the pancreas, brain, and gastrointestinal tract, semaglutide reduces appetite, slows gastric emptying, enhances insulin secretion, and suppresses glucagon release — leading to reduced food intake and improved blood sugar control.

Semaglutide is FDA-approved under multiple brand names for different indications. It was originally developed for type 2 diabetes (Ozempic) and later approved at a higher dose for chronic weight management (Wegovy). An oral formulation (Rybelsus) is also available. Compounding pharmacies produce non-branded versions, though these are not FDA-approved. This guide covers dosing protocols across all formulations.

Use our Peptide Dosage to assist with reconstitution and dose calculations for compounded semaglutide.

Dosing information in this guide is derived from clinical studies, published research, and community protocols.

Brand Names & Formulations

Brand	Indication	Route	Max Dose	FDA-Approved
Ozempic	Type 2 Diabetes	SubQ injection (weekly)	2.0mg/week	Yes (2017)
Wegovy	Chronic Weight Management	SubQ injection (weekly)	2.4mg/week	Yes (2021)
Rybelsus	Type 2 Diabetes	Oral tablet (daily)	14mg/day	Yes (2019)
Compounded	Varies (off-label)	SubQ injection (weekly)	Varies by pharmacy	No

Key Characteristics:

GLP-1 receptor agonist — mimics the incretin hormone GLP-1 to reduce appetite, slow gastric emptying, and improve glycemic control
Long half-life (~1 week) — albumin binding extends the half-life to approximately 7 days, enabling once-weekly dosing
Central appetite suppression — acts on GLP-1 receptors in the hypothalamus to reduce hunger and increase satiety signaling
Delayed gastric emptying — slows the rate at which food leaves the stomach, contributing to reduced food intake and post-meal glucose control
Cardiovascular benefit — the SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events in overweight/obese adults without diabetes
Dose-dependent efficacy — higher doses (2.4mg vs 1.0mg) produce greater weight loss but also more GI side effects, making titration essential

For a complete overview of its mechanism and research, see our full Semaglutide profile. New to peptides? Start with the Beginner's Guide to Peptides.

How Semaglutide Dosage Is Determined

Semaglutide dosing is backed by one of the strongest clinical evidence bases of any peptide-class medication. Dosage recommendations are derived from large, randomized, placebo-controlled trials — the STEP program for weight management and the SUSTAIN program for type 2 diabetes — involving thousands of participants over 52–104 weeks.

STEP Trials (Weight Management)

The Semaglutide Treatment Effect in People with obesity (STEP) program is a series of phase 3 trials that established 2.4mg/week as the target dose for weight loss. STEP 1 enrolled over 1,900 adults with BMI ≥30 (or ≥27 with a weight-related comorbidity) and demonstrated a mean weight loss of approximately 15% of body weight at 68 weeks compared to approximately 2.4% with placebo. STEP 2–5 confirmed these results across different populations, including those with type 2 diabetes.

SUSTAIN Trials (Type 2 Diabetes)

The SUSTAIN program evaluated semaglutide for glycemic control across 10+ trials. SUSTAIN 1–10 established that 0.5mg and 1.0mg weekly injections significantly reduced HbA1c (by 1.5–1.8 percentage points) and produced secondary weight loss of 4–6kg. Semaglutide consistently outperformed other GLP-1 agonists (dulaglutide, exenatide) and oral diabetes medications in head-to-head comparisons.

SELECT Trial (Cardiovascular)

The SELECT trial enrolled over 17,600 overweight or obese adults with established cardiovascular disease but without diabetes. Semaglutide 2.4mg/week demonstrated a 20% reduction in the composite endpoint of cardiovascular death, non-fatal heart attack, and non-fatal stroke — leading to a new FDA indication for cardiovascular risk reduction.

Titration Rationale

All trials used a gradual dose escalation (titration) over 16–20 weeks. The titration reduces gastrointestinal side effects (nausea, vomiting, diarrhea) that occur when semaglutide is started at higher doses. Approximately 80% of GI side effects occur during dose escalation phases and are typically mild-to-moderate and transient.

Strength of evidence: Strong. Semaglutide's dosing is supported by some of the largest and most rigorous clinical trials in metabolic medicine. The STEP, SUSTAIN, and SELECT programs collectively enrolled over 25,000 participants across multinational, double-blind, placebo-controlled trials with 52–104 week follow-up periods. This is among the strongest evidence bases available for any peptide or peptide-class medication.

Official Titration Schedules

Titration is not optional — it is a core part of the semaglutide protocol. Each formulation has a specific dose escalation schedule designed to minimize side effects while reaching the therapeutic maintenance dose. Never skip titration steps.

Wegovy Titration Schedule (Weight Management)

Phase	Weeks	Dose	Notes
Month 1	Weeks 1–4	0.25mg/week	Starting dose; assess tolerance
Month 2	Weeks 5–8	0.5mg/week	First escalation; most GI side effects emerge here
Month 3	Weeks 9–12	1.0mg/week	Significant appetite suppression typically begins
Month 4	Weeks 13–16	1.7mg/week	Continue if tolerating; do not skip to 2.4mg
Month 5+	Week 17 onward	2.4mg/week	Full maintenance dose for weight management

Ozempic Titration Schedule (Type 2 Diabetes)

Phase	Weeks	Dose	Notes
Month 1	Weeks 1–4	0.25mg/week	Starting dose; not a therapeutic dose for glycemic control
Month 2+	Weeks 5–8	0.5mg/week	First therapeutic dose; assess HbA1c response at 8 weeks
Optional increase	Week 9+	1.0mg/week	If additional glycemic control needed after ≥4 weeks at 0.5mg
Optional increase	Week 13+	2.0mg/week	Maximum dose; if additional control needed after ≥4 weeks at 1.0mg

Compounded Semaglutide Titration (Typical Protocol)

Phase	Weeks	Dose	Notes
Month 1	Weeks 1–4	0.25mg/week	Starting dose; identical to brand titration
Month 2	Weeks 5–8	0.5mg/week	First escalation; monitor GI tolerance
Month 3	Weeks 9–12	1.0mg/week	Many providers hold here if adequate response achieved
Month 4	Weeks 13–16	1.25–1.5mg/week	Intermediate step; compounded protocols often include this
Month 5+	Week 17 onward	1.5–2.5mg/week	Maintenance; provider-guided based on response

Titration tip: If you experience persistent nausea at a new dose level, stay at that dose for an additional 2–4 weeks before escalating. It is better to extend the titration timeline than to push through severe GI side effects. Your provider can help you decide when to advance.

Ozempic vs Wegovy vs Compounded Semaglutide

All three contain the same active molecule — semaglutide — but differ in FDA approval status, dosing ranges, delivery format, cost, and availability. Here is a side-by-side comparison:

Feature	Ozempic	Wegovy	Compounded
FDA-Approved	Yes (Type 2 Diabetes)	Yes (Weight Management)	No
Max Dose	2.0mg/week	2.4mg/week	Varies (typically up to 2.5mg)
Delivery	Pre-filled pen (multi-dose)	Pre-filled pen (single-dose)	Vial (requires reconstitution)
Dose Flexibility	Fixed increments (0.25, 0.5, 1.0, 2.0)	Fixed increments (0.25, 0.5, 1.0, 1.7, 2.4)	Fully adjustable (any dose via syringe)
Insurance Coverage	Often covered for T2D	Varies; limited for weight loss	Not covered
Cost (approx.)	$800–1,000/month (list price)	$1,300–1,600/month (list price)	$100–400/month
Quality Assurance	FDA manufacturing standards	FDA manufacturing standards	Varies by pharmacy; check 503A/503B status

On compounded semaglutide: The FDA has issued warnings about certain compounded GLP-1 products. Some compounding pharmacies use semaglutide sodium salt rather than the base form used in Ozempic and Wegovy, and the FDA considers these to be different active ingredients. If using compounded semaglutide, verify that the pharmacy is a registered 503A or 503B facility, request certificates of analysis, and work with a licensed prescriber who monitors your treatment.

Reconstitution Guide (Compounded Semaglutide)

Brand-name Ozempic and Wegovy come in pre-filled pens — no reconstitution needed. Compounded semaglutide, however, is typically supplied as a lyophilized (freeze-dried) powder that must be reconstituted with bacteriostatic water (BAC water) before injection.

Note: Some compounding pharmacies supply semaglutide pre-mixed in solution, eliminating the need for reconstitution. Always follow the specific instructions provided by your compounding pharmacy.

Supplies Needed:

Compounded semaglutide vial (lyophilized powder)
Bacteriostatic water (BAC water) for injection
Insulin syringes (0.5mL or 1.0mL, 29–31 gauge)
Alcohol swabs
Sharps disposal container

Steps

Wash Hands & Prepare Workspace

Wash hands thoroughly with soap and water. Ensure a clean, flat workspace. Gather all supplies.

Swab the Vial Tops

Wipe the tops of both the semaglutide vial and the BAC water vial with alcohol swabs. Allow to air dry for 10–15 seconds.

Draw BAC Water

Using a new syringe, draw the prescribed amount of bacteriostatic water. The amount depends on the vial strength and your target concentration — see the chart below.

Inject BAC Water into Semaglutide Vial

Insert the needle through the rubber stopper and slowly inject the BAC water down the inside wall of the vial. Do NOT spray directly onto the powder — this can damage the peptide.

Swirl Gently — Do Not Shake

Gently roll or swirl the vial between your fingers until the powder is fully dissolved. The solution should be clear and colorless. Never shake — shaking can denature the peptide.

Label & Refrigerate

Label the vial with the reconstitution date and concentration. Store refrigerated at 2–8°C. Use within 28 days. Never freeze reconstituted semaglutide.

Reconstitution Quick Reference Chart

Vial Size	BAC Water	Concentration	0.25mg Dose	0.5mg Dose	1.0mg Dose
2mg vial	2.0mL	1.0mg/mL	0.25mL (25 units)	0.50mL (50 units)	1.00mL (100 units)
5mg vial	2.0mL	2.5mg/mL	0.10mL (10 units)	0.20mL (20 units)	0.40mL (40 units)
5mg vial	2.5mL	2.0mg/mL	0.125mL (12.5 units)	0.25mL (25 units)	0.50mL (50 units)
10mg vial	2.0mL	5.0mg/mL	0.05mL (5 units)	0.10mL (10 units)	0.20mL (20 units)

Skip the Math — Use Our

Enter your vial size, BAC water volume, and desired dose — get instant calculations with zero manual math.

For detailed reconstitution instructions applicable to all peptides, see our Reconstitution Guide.

Semaglutide Dosage by Goal

Semaglutide's dosing varies depending on the primary treatment goal. Higher doses are used for weight management than for glycemic control alone. All protocols begin with the same low-dose titration.

Weight Loss

The FDA-approved protocol for chronic weight management (Wegovy) targets a maintenance dose of 2.4mg/week. In the STEP 1 trial, participants on 2.4mg/week lost approximately 15% of body weight over 68 weeks. Weight loss is dose-dependent — higher maintenance doses produce greater results but also more GI side effects during titration.

Target dose: 2.4mg/week (Wegovy protocol)
Titration: 16–20 weeks (see titration schedule above)
Route: SubQ injection, once weekly
Duration: Long-term (weight regain is common after discontinuation)
Key requirement: Adequate protein intake (1.2–1.6g/kg/day) and resistance training to preserve lean mass

Type 2 Diabetes (Glycemic Control)

For type 2 diabetes, lower doses (0.5–2.0mg/week) are typically sufficient for meaningful HbA1c reduction. Many patients achieve adequate glycemic control at 0.5–1.0mg and do not need to escalate further unless additional weight loss is also a goal.

Target dose: 0.5–2.0mg/week (Ozempic protocol)
Titration: Start at 0.25mg for 4 weeks, then 0.5mg; increase as needed
Route: SubQ injection, once weekly
Duration: Long-term (chronic disease management)
Monitoring: HbA1c and fasting glucose every 3 months during titration

Body Composition Optimization

Some users aim to reduce body fat while preserving or building lean mass. This typically involves semaglutide at moderate doses (1.0–1.7mg/week) combined with structured resistance training, high protein intake, and sometimes adjunctive peptides for muscle preservation and recovery. This is an off-label use.

Target dose: 1.0–1.7mg/week (lower than full weight-loss dose)
Protein target: 1.4–1.6g/kg/day minimum
Resistance training: 3–4 sessions per week (essential for lean mass preservation)
Optional stacking: See Stacking section below

Dose-response context: Higher doses produce more weight loss but also more side effects. Many compounded semaglutide users and some prescribers find that 1.0–1.7mg/week provides a good balance of efficacy and tolerability for patients who are not severely obese. Work with your provider to find the lowest effective dose for your goals.

Semaglutide Injection Guide

Injection Protocol (Weekly SubQ)

Choose Your Injection Day

Pick a consistent day each week (e.g., every Friday). Semaglutide is injected once per week on the same day. You can change the day if needed, as long as at least 2 days (48 hours) have passed since the last injection.

Wash Hands & Prepare Supplies

Wash hands with soap and water. Gather your pen or syringe, alcohol swabs, and sharps container. If using a compounded vial, draw the prescribed dose into an insulin syringe.

Select Injection Site

Inject subcutaneously (under the skin, into the fat layer) in one of three areas: abdomen (at least 2 inches from the navel), front of thigh, or upper arm. Rotate sites each week to prevent lipodystrophy.

Clean the Injection Site

Swab the injection area with an alcohol wipe using a circular motion. Allow to air dry completely before injecting.

Inject

Pinch a fold of skin at the injection site. Insert the needle at a 90-degree angle (or 45 degrees if very lean). Inject slowly and steadily. Hold the needle in place for 5–10 seconds after the plunger is fully depressed, then withdraw.

Dispose & Record

Place the used needle in a sharps container immediately. Do not recap. Record the date, dose, injection site, and any side effects in a log.

Timing & Missed Doses

Best time of day: Any time — semaglutide can be injected morning or evening, with or without food. Choose a time you can be consistent with.
Missed dose (within 5 days): Take the missed dose as soon as you remember, then resume your regular schedule.
Missed dose (more than 5 days late): Skip the missed dose entirely. Take the next dose on your regular scheduled day.
Never double dose: Do not take two injections within 48 hours to make up for a missed dose.

Injection tip: Many users find that injecting in the evening or before bed minimizes the perception of nausea during the first few hours after injection. If injection-day nausea is an issue, try switching to an evening injection.

Managing Semaglutide Side Effects

Gastrointestinal side effects are the most common reason people discontinue semaglutide. Most GI side effects are dose-dependent, occur during titration, and improve over time. Proactive management significantly improves tolerability.

Side Effects by Frequency

Side Effect	Frequency	Onset	Management
Nausea	Very common (40–44%)	During titration	Eat smaller meals; avoid fatty/spicy food; ginger tea
Diarrhea	Common (30%)	During titration	Stay hydrated; avoid dairy and high-fiber on injection day
Vomiting	Common (24%)	During titration	Small frequent sips of water; bland foods; extend titration if persistent
Constipation	Common (24%)	Ongoing	Increase water intake; fiber supplementation; consider stool softener
Abdominal pain	Common (20%)	During titration	Smaller portions; avoid carbonated drinks; contact provider if severe
Headache	Common (14%)	First few weeks	Adequate hydration; usually resolves with continued use
Fatigue	Uncommon (11%)	During titration	Ensure adequate caloric intake; get enough sleep; usually transient
Injection site reaction	Uncommon (<5%)	Any time	Rotate injection sites; ensure room temperature injection

Titration Tips for GI Tolerance

Eat smaller, more frequent meals — 4–5 small meals per day instead of 2–3 large ones
Reduce fatty and fried foods — fat slows digestion further on top of semaglutide's gastric-slowing effect
Stop eating when satisfied, not full — the delayed gastric emptying means “full” hits later; overeating causes significant discomfort
Stay hydrated — aim for 64oz+ (2L+) of water daily; dehydration worsens constipation and nausea
Extend the titration — if side effects are limiting at any dose, stay at that dose for an extra 2–4 weeks before increasing
Avoid lying down immediately after eating — upright posture reduces GERD and nausea

Seek immediate medical attention if you experience: severe persistent abdominal pain (especially radiating to the back), inability to keep any fluids down for 24+ hours, signs of allergic reaction (swelling, difficulty breathing, rash), or symptoms of pancreatitis. These are uncommon but serious complications that require urgent evaluation.

Cycle Duration & Maintenance

Semaglutide is designed for long-term use. Unlike peptides that are cycled (on/off), semaglutide for both diabetes and weight management is intended as ongoing therapy. Discontinuation typically leads to weight regain and return of elevated blood glucose. However, some patients choose to taper down to a lower maintenance dose after achieving their goals.

Dose Maintenance Strategies

Strategy	Dose Range	Duration	Notes
Full maintenance	2.4mg/week	Indefinite	FDA-recommended; maximum weight loss maintenance
Reduced maintenance	1.0–1.7mg/week	Indefinite	Some providers taper to lower dose after target weight; fewer side effects
Intermittent use	Varies	Cycles (e.g., 6 months on, 3 months off)	Not well studied; some weight regain expected during off periods
Gradual discontinuation	Taper through titration doses in reverse	8–16 weeks taper	Reduces rebound appetite; establish habits before stopping

What Happens After Discontinuation

Appetite returns — GLP-1 receptor stimulation ceases within 1–2 weeks of the last dose (half-life ~1 week)
Weight regain — the STEP 1 extension data showed participants regained approximately two-thirds of lost weight within one year of stopping
Blood sugar rises — for type 2 diabetes patients, glycemic control will deteriorate without alternative management
Gradual taper is preferred — stepping down through titration doses in reverse (2.4 → 1.7 → 1.0 → 0.5 → stop) over 8–16 weeks reduces the shock of abrupt appetite return

Best practice for discontinuation: Before stopping semaglutide, ensure you have established sustainable dietary habits, a consistent exercise routine (including resistance training), and adequate protein intake. The patients who maintain the most weight loss after stopping are those who built these habits during treatment.

Stacking Semaglutide with Other Peptides

Some practitioners and users combine semaglutide with other peptides to target different aspects of body composition and recovery. These are off-label combinations — discuss any stacking protocol with your prescriber before starting.

Semaglutide + AOD-9604 (Appetite Suppression + Fat Metabolism)

AOD-9604 is a modified fragment of human growth hormone (hGH fragment 176–191) that stimulates lipolysis (fat breakdown) without the growth-promoting or blood-sugar-raising effects of full hGH. When combined with semaglutide, the rationale is to enhance fat loss through two independent mechanisms — reduced caloric intake (semaglutide) plus enhanced fat metabolism (AOD-9604).

Compound	Dose	Frequency	Purpose
Semaglutide	Per titration schedule	Once weekly (SubQ)	Appetite suppression, caloric reduction
AOD-9604	250–300mcg/day	Daily (SubQ, fasted AM)	Enhanced lipolysis, fat metabolism support

Semaglutide + Muscle Preservation Peptides (Fat Loss + Lean Mass Support)

One of the primary concerns with semaglutide-induced weight loss is lean mass loss. Some practitioners add peptides that support recovery, tissue repair, and growth hormone secretion to help preserve muscle during caloric restriction. Common additions include BPC-157 for tissue recovery and CJC-1295 / Ipamorelin for GH secretion.

Compound	Dose	Frequency	Purpose
Semaglutide	Per titration schedule	Once weekly (SubQ)	Appetite suppression, weight loss
BPC-157	250–500mcg/day	1–2x daily (SubQ)	Tissue repair, gut health, recovery support
CJC-1295 / Ipamorelin	100mcg each / dose	1–2x daily (SubQ, before bed)	GH secretion, lean mass preservation, recovery

Do NOT combine semaglutide with tirzepatide (Mounjaro/Zepbound) or any other GLP-1 receptor agonist. Both drugs target the same receptor. Combining them provides no additional benefit and significantly increases the risk of severe gastrointestinal side effects, dehydration, and potential pancreatitis. If switching between GLP-1 agents, allow an appropriate washout period as directed by your prescriber.

Explore more combinations with our Peptide Stack Builder or browse the Top 10 Peptide Stacks guide.

Safety, Side Effects & Contraindications

BLACK BOX WARNING — Thyroid C-Cell Tumors: In rodent studies, semaglutide caused dose-dependent thyroid C-cell tumors (medullary thyroid carcinoma). It is unknown whether semaglutide causes thyroid C-cell tumors in humans. Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk and symptoms of thyroid tumors.

Serious Risks

Pancreatitis — acute pancreatitis has been reported. Discontinue promptly if pancreatitis is suspected (persistent severe abdominal pain, with or without vomiting). Do not restart if pancreatitis is confirmed.
Gallbladder disease — cholelithiasis (gallstones) and cholecystitis have been reported in clinical trials, likely related to rapid weight loss.
Acute kidney injury — reported in patients with dehydration from GI side effects (nausea, vomiting, diarrhea). Maintain adequate hydration.
Diabetic retinopathy complications — rapid improvement in glycemic control can temporarily worsen diabetic retinopathy. Monitor eye health.
Hypoglycemia — when used with insulin or sulfonylureas, risk of low blood sugar increases. Dose adjustments of concurrent medications may be needed.
Suicidal ideation — the FDA is evaluating post-marketing reports of suicidal thoughts and self-harm. Patients should report any changes in mood or behavior to their provider immediately.

Contraindications

Personal or family history of medullary thyroid carcinoma (MTC)
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Known hypersensitivity to semaglutide or any excipient in the formulation
Pregnancy (Category X) — discontinue at least 2 months before a planned pregnancy
History of pancreatitis — use with extreme caution or avoid

Drug Interactions

Insulin and sulfonylureas — increased risk of hypoglycemia; dose reduction of insulin/sulfonylurea may be required
Oral medications — semaglutide delays gastric emptying, which may affect the absorption rate of co-administered oral medications (particularly those with narrow therapeutic windows like warfarin or levothyroxine)
Other GLP-1 agonists — do not combine with any other GLP-1 or dual GIP/GLP-1 agonist (Tirzepatide, liraglutide, dulaglutide, etc.)
Oral contraceptives — delayed gastric emptying may reduce absorption; consider additional contraceptive methods during initial treatment and dose escalations

Lab monitoring: Baseline and periodic monitoring should include HbA1c, fasting glucose, lipid panel, comprehensive metabolic panel (kidney/liver function), amylase and lipase, thyroid panel (TSH, free T4), and CBC. Frequency is typically every 3–6 months, guided by your provider.

Common Semaglutide Mistakes

These are the most frequent errors that reduce semaglutide's effectiveness or cause preventable side effects:

Skipping the titration and starting at a high dose: The titration exists to allow your GI system to adapt. Starting at 1.0mg or higher without titrating causes severe nausea, vomiting, and diarrhea in most people, and dramatically increases dropout rates.

Eating large or high-fat meals on injection day: Semaglutide slows gastric emptying. Large, fatty meals on injection day — when the drug concentration peaks — are more likely to cause nausea, bloating, and reflux. Eat smaller, lighter meals for 24–48 hours after injection.

Not consuming enough protein: Semaglutide suppresses appetite broadly, making it easy to undereat protein. Without adequate protein (1.2–1.6g/kg/day) and resistance training, a disproportionate amount of weight lost will be muscle mass rather than fat.

Stopping abruptly without a taper or maintenance plan: The STEP 1 extension data shows significant weight regain after abrupt discontinuation. A gradual taper (stepping down through titration doses in reverse) combined with established exercise and dietary habits gives the best chance of maintaining results.

Using compounded semaglutide without verifying pharmacy credentials: Not all compounding pharmacies maintain the same quality standards. Use only 503A or 503B registered pharmacies with third-party testing. The FDA has issued warnings about substandard compounded GLP-1 products containing incorrect doses or contaminants.

Ignoring persistent GI warning signs: Mild nausea during titration is expected. However, persistent vomiting, severe abdominal pain radiating to the back, or inability to keep fluids down may indicate pancreatitis or gallbladder disease — both known risks. Seek medical attention immediately for severe symptoms.

Doubling up after a missed dose: If you miss your weekly injection, take it as soon as possible if within 5 days of the scheduled date. If more than 5 days late, skip the missed dose and take the next one on schedule. Never take two doses within 48 hours — this increases side effects without improving outcomes.

Not drinking enough water: Semaglutide slows gastric emptying and reduces appetite, which often leads to reduced fluid intake. Dehydration worsens constipation (a common side effect), increases the risk of kidney issues, and can cause dizziness. Aim for at least 64oz (2L) of water daily.

Frequently Asked Questions

Key Takeaways

Semaglutide is a GLP-1 receptor agonist — FDA-approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy)
Titration is essential — always start at 0.25mg/week and follow the 16–20 week dose escalation schedule to minimize GI side effects
Maintenance dose for weight loss: 2.4mg/week (Wegovy); for diabetes: 0.5–2.0mg/week (Ozempic)
Evidence base is very strong — STEP, SUSTAIN, and SELECT trials involved over 25,000 participants with follow-up of 52–104 weeks
GI side effects are most common during titration — nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%); typically improve over time
Black box warning: thyroid C-cell tumors in rodents; contraindicated with personal/family history of MTC or MEN 2
Preserve lean mass — high protein intake (1.2–1.6g/kg/day) and resistance training are essential during treatment
Do NOT combine with other GLP-1 agonists (liraglutide, dulaglutide, Tirzepatide)
Weight regain is common after stopping — taper gradually and establish sustainable habits before discontinuation
Requires a prescription — work with a licensed healthcare provider for dosing, monitoring, and lab work

This article is for educational and informational purposes only. See our Disclaimer.

References

Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” N Engl J Med. 2021;384(11):989-1002. (STEP 1) PubMed
Davies M, et al. “Semaglutide 2.4mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2).” Lancet. 2021;397(10278):971-984. PubMed
Wadden TA, et al. “Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy (STEP 3).” JAMA. 2021;325(14):1403-1413. PubMed
Rubino D, et al. “Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4).” JAMA. 2021;325(14):1414-1425. PubMed
Lincoff AM, et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.” N Engl J Med. 2023;389(24):2221-2232. (SELECT) PubMed
Marso SP, et al. “Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.” N Engl J Med. 2016;375(19):1834-1844. (SUSTAIN-6) PubMed
Novo Nordisk. Ozempic (semaglutide injection) Prescribing Information. Revised 2024.
Novo Nordisk. Wegovy (semaglutide injection) Prescribing Information. Revised 2024.
Wilding JPH, et al. “Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP 1 extension).” Diabetes Obes Metab.2022;24(8):1553-1564. PubMed
FDA Safety Communication. “FDA warns about compounded versions of semaglutide.” 2023.

Next Steps

Continue your research with these resources.

AOD-9604 Dosage Guide

Explore dosing protocols for AOD-9604, a fat metabolism peptide commonly stacked with semaglutide.

View Guide

Dosage Calculator

Calculate reconstitution volumes and injection doses for compounded semaglutide vials.

Open Calculator

Peptide Directory

Browse all peptides with research summaries and dosing data.

View Directory